Glasdegib - Pfizer

Drug Profile

Glasdegib - Pfizer

Alternative Names: PF 04; PF-04449913; PF-4449913

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Netherlands Cancer Institute; Pfizer
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Phase I/II Chronic myelomonocytic leukaemia; Graft-versus-host disease
  • Phase I Cancer; Haematological malignancies
  • No development reported Solid tumours

Most Recent Events

  • 09 Nov 2017 Glasdegib is still in phase-I development in Acute-myeloid-leukaemia (Combination therapy, First-line therapy) in Japan (PO, Tablet) (NCT02038777)
  • 09 Nov 2017 Glasdegib is still in phase-I development in Haematological-malignancies (Late-stage disease, Monotherapy, Second-line therapy or greater) in Japan (PO, Tablet) (NCT02038777)
  • 09 Nov 2017 Glasdegib is still in phase-I development in Myelodysplastic-syndromes (Combination therapy, First-line therapy) in Japan (PO, Tablet) (NCT02038777)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top